ADPT

Adaptive Biotechnologies Corporation

Halal Rating :
Uncomfortable
Last Price $6.23 Last updated:
Market Cap $693.12m
7D Change -4.45%
1 Year Change 23.37%
Company Overview Use of Interest Company Impact Justification for our Halal Rating Recent News

Company Overview

Industries
  • Manufacturing
  • Pharmaceutical Products
  • Biological Products
  • Except Diagnostic Substances
Exchange NASDAQ
Next Earnings Date Nov. 7, 2024

Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company that focuses on developing immune-driven clinical products to diagnose, treat, and monitor various diseases. The company's platform leverages immune system data through proprietary technologies to develop products for various therapeutic areas including cancer, autoimmune conditions, and infectious diseases.

The company generates revenue primarily through immune medicine products and services, including clinical testing and research services. Their main products include clonoSEQ for detecting and monitoring minimal residual disease (MRD) in blood cancers, and T-Detect for identifying T cell responses to various diseases.

Use of Interest

Reporting Date Total Revenue Total Operating Expense Interest Income Interest Expense Interest Income Ratio Interest Expense Ratio
Sept. 30, 2024 $46.44m $82.01m - $2.94m 0.00% 3.58%
June 30, 2024 $43.19m $93.2m - $2.7m 0.00% 2.89%
March 31, 2024 $41.87m $93.63m - $2.99m 0.00% 3.20%

Company Impact

Help us evaluate Adaptive Biotechnologies Corporation's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.

Contribute

Recent News & Updates